Inflammation is a conserved biological response essential for host defense; however, its dysregulation contributes to a broad spectrum of chronic diseases, including autoimmune, cardiovascular, metabolic, neurodegenerative, and malignant disorders. Over recent decades, advances in molecular immunology have shifted the conceptual framework of inflammation from a linear cascade to a complex, network-based regulatory system, in which therapeutic efficacy depends on precise modulation of interconnected signaling pathways rather than broad immunosuppression. Despite the clinical success of biologics targeting tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), as well as small-molecule inhibitors such as Janus kinase (JAK) inhibitors, long-term disease control remains limited due to cytokine redundancy, compensatory signaling, and underlying disease heterogeneity. Intracellular signaling hubs such as nuclear factor-κB (NF-κB) and innate immune complexes including the NLRP3 inflammasome further illustrate the challenge of targeting central regulatory nodes that are simultaneously essential for physiological immune homeostasis. This commentary emphasizes that inflammatory diseases should be understood as emergent properties of adaptive immune networks rather than isolated molecular events. Mechanistic and translational relevance of this perspective lies in integrating cytokine signaling, intracellular pathways, and inflammasome biology within a systems-level framework that explains both therapeutic success and failure of current interventions. Such an integrated view highlights the limitations of single-target strategies and supports a shift toward network-informed and patient-specific approaches. Future therapeutic development will likely depend on causal network modeling, multi-omics integration, and biomarker-guided stratification to enable precision immunomodulation. This paradigm shift from pathway-centric inhibition to dynamic regulation of immune networks may provide more durable and mechanistically grounded strategies for the treatment of chronic inflammatory diseases.